© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Roche Holding AG (RHHVF) stock surged +1.42%, trading at $430.78 on OTC, up from the previous close of $424.75. The stock opened at $423.23, fluctuating between $412.49 and $430.78 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | 423.23 | 435.87 | 412.49 | 430.78 | 185 |
| Sep 10, 2026 | 418.25 | 434.27 | 417.84 | 424.75 | 508 |
| Sep 09, 2026 | 426.98 | 439.29 | 426.17 | 427.93 | 732 |
| Sep 08, 2026 | 430.76 | 443.56 | 426.05 | 439.57 | 249 |
| Sep 04, 2026 | 449.19 | 450.44 | 429.10 | 442.17 | 8.14K |
| Sep 03, 2026 | 439.32 | 441.86 | 439.15 | 441.86 | 3.04K |
| Sep 02, 2026 | 425.28 | 435.57 | 425.28 | 429.45 | 3.19K |
| Sep 01, 2026 | 429.00 | 430.00 | 425.37 | 425.37 | 45.56K |
| Aug 31, 2026 | 448.89 | 448.89 | 428.50 | 428.92 | 824 |
| Aug 28, 2026 | 455.19 | 458.48 | 436.83 | 453.07 | 280 |
| Aug 27, 2026 | 444.90 | 463.42 | 444.90 | 462.61 | 705 |
| Aug 26, 2026 | 466.05 | 469.25 | 452.56 | 465.42 | 15.17K |
| Aug 25, 2026 | 466.89 | 468.00 | 459.94 | 461.80 | 89 |
| Aug 24, 2026 | 468.10 | 468.10 | 459.36 | 459.36 | 499 |
| Aug 21, 2026 | 473.20 | 474.23 | 451.30 | 468.60 | 633 |
| Aug 20, 2026 | 462.30 | 465.50 | 453.46 | 458.51 | 13.88K |
| Aug 19, 2026 | 455.00 | 465.12 | 455.00 | 465.12 | 2.08K |
| Aug 18, 2026 | 444.00 | 444.00 | 444.00 | 444.00 | 825 |
| Aug 17, 2026 | 432.51 | 450.27 | 432.51 | 436.06 | 1.47K |
| Aug 14, 2026 | 440.67 | 451.47 | 432.49 | 433.58 | 5.19K |
Roche Holding AG operates as a global healthcare leader, specializing in both pharmaceuticals and diagnostics. The company's reach extends across key markets like Switzerland, Germany, and the United States, in addition to its broader international footprint. Its extensive pharmaceutical division develops and offers treatments for a diverse range of conditions. These therapeutic areas encompass critical fields such as oncology (cancer), neuroscience, infectious diseases, immunology, hemophilia, ophthalmology (eye care), dermatology (skin conditions), respiratory illnesses, anemia, inflammatory and autoimmune disorders, and transplantation. Beyond medicinal products, Roche is also a prominent supplier of in vitro diagnostic tests. These tests are vital for identifying numerous diseases, including various cancers, cardiovascular conditions, diabetes, COVID-19, hepatitis, and human papillomavirus (HPV). Complementing its testing services, the company provides the essential diagnostic instruments and chemical reagents necessary for these procedures. Demonstrating its commitment to innovation, Roche has established a research partnership with Synlogic, Inc. This collaboration aims to discover a novel synthetic biotic designed specifically for the treatment of inflammatory bowel disease (IBD). Tracing its origins back to its founding in 1896, Roche Holding AG is headquartered in Basel, Switzerland.
| Employees | 103249 |
| Beta | 0.35 |
| Sales or Revenue | $60.44B |
| 5Y Sales Change% | 0.086% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |